STUDY DESIGN: In a retrospective analysis we evaluated the achieved and the predicted survival times according to the Tokuhashi score for patients with spinal metastases of lung cancer (lc). OBJECTIVE: Our aim was to investigate the robustness of the Tokuhashi Score for this group of patients. SUMMARY OF BACKGROUND DATA: The decision on operative versus conservative treatment for cancer patients with vertebral metastases depend on their predicted lifespan. Although the score of Tokuhashi is commonly used for prognostic predictions, it's reliability for specific tumor types (e.g., lc), has not been validated. METHODS: Seventy-six patients who had undergone spinal surgery for lc metastases between 1999 and 2004 were verified according to the Tokuhashi score and predicted versus achieved survival times were compared. RESULTS: The median overall survival (OS) after surgery for all patients was 108 (3-1767) days (102 [5-1767] days for patients with NSCLC [n = 49; 64.5%] and 108 [3-473] days for patients with SCLC [n = 24; 31.6%]). Survival times differed depending on the time period of procedure performance (OS 81 [3-435] days for patients operated between 1999 and 2001 [n = 38], 135 [8-1767] days for patients who received surgery between 2002 and 2004 [n = 38]). Actual and predicted survival were similar in 51 of 76 cases (67.1%), while there was no correlation in 25 of 76 (32.9%) cases. Results were comparable for all histologic subgroups. CONCLUSION: Although the survival time of patients with vertebral metastases from lc has increased over the last 10 years, the overall outcome is still poor. For the prediction of an individual prognosis in the group of lc patients the score of Tokuhashi seems to be a suboptimal tool. We conclude that therapeutic decisions for such patients should be made based on interdisciplinary platforms, especially in the light of improved systemic treatment options.
STUDY DESIGN: In a retrospective analysis we evaluated the achieved and the predicted survival times according to the Tokuhashi score for patients with spinal metastases of lung cancer (lc). OBJECTIVE: Our aim was to investigate the robustness of the Tokuhashi Score for this group of patients. SUMMARY OF BACKGROUND DATA: The decision on operative versus conservative treatment for cancerpatients with vertebral metastases depend on their predicted lifespan. Although the score of Tokuhashi is commonly used for prognostic predictions, it's reliability for specific tumor types (e.g., lc), has not been validated. METHODS: Seventy-six patients who had undergone spinal surgery for lc metastases between 1999 and 2004 were verified according to the Tokuhashi score and predicted versus achieved survival times were compared. RESULTS: The median overall survival (OS) after surgery for all patients was 108 (3-1767) days (102 [5-1767] days for patients with NSCLC [n = 49; 64.5%] and 108 [3-473] days for patients with SCLC [n = 24; 31.6%]). Survival times differed depending on the time period of procedure performance (OS 81 [3-435] days for patients operated between 1999 and 2001 [n = 38], 135 [8-1767] days for patients who received surgery between 2002 and 2004 [n = 38]). Actual and predicted survival were similar in 51 of 76 cases (67.1%), while there was no correlation in 25 of 76 (32.9%) cases. Results were comparable for all histologic subgroups. CONCLUSION: Although the survival time of patients with vertebral metastases from lc has increased over the last 10 years, the overall outcome is still poor. For the prediction of an individual prognosis in the group of lc patients the score of Tokuhashi seems to be a suboptimal tool. We conclude that therapeutic decisions for such patients should be made based on interdisciplinary platforms, especially in the light of improved systemic treatment options.
Authors: Carmine Zoccali; Jesse Skoch; Christina M Walter; Mohammad Torabi; Mark Borgstrom; Ali A Baaj Journal: Eur Spine J Date: 2015-12-01 Impact factor: 3.134
Authors: C Bouthors; S Prost; C Court; B Blondel; Y P Charles; S Fuentes; H P Mousselard; C Mazel; C H Flouzat-Lachaniette; P Bonnevialle; F Saihlan Journal: Support Care Cancer Date: 2019-08-09 Impact factor: 3.603
Authors: Laurens Bollen; Yvette M van der Linden; Willem Pondaag; Marta Fiocco; Bas P M Pattynama; Corrie A M Marijnen; Rob G H H Nelissen; Wilco C Peul; P D Sander Dijkstra Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300